cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.24146763.v1
title: Supplementary Material for: Impact of 14 days of bed rest in older adults and an exercise countermeasure on body composition, muscle strength and cardiovascular function: Canadian Space Agency standard measures

description: Introduction: Head-down bed rest (HDBR) has long been used as an analog to microgravity and it also enables studying the changes occurring with aging. Exercise is the most effective countermeasure for the deleterious effects of inactivity. The aim of this study was to investigate the efficacy of an exercise countermeasure in healthy older participants on attenuating musculoskeletal deconditioning, cardiovascular fitness level and muscle strength during l4 days of HDBR as part of the standard measures of the Canadian Space Agency. Methods: Twenty-three participants (12 males and 11 females), aged 55-65 years, were admitted for a 26-day inpatient stay at the McGill University Health Centre. After 5 days of baseline assessment tests, they underwent 14 days of continuous HDBR followed by 7 days of recovery with repeated tests. Participants were randomized to passive physiotherapy or an exercise countermeasure during the HDBR period consisting in 3 sessions per day of either high-intensity interval training (HIIT) or low-intensity cycling or strength exercises for the lower and upper body. Peak aerobic power (V̇O2peak) was determined using indirect calorimetry. Body composition was assessed by dual-energy X-ray absorptiometry (DXA) and several muscle group strengths were evaluated using an adjustable chair dynamometer. A vertical jump was used to assess whole-body power output and a tilt test to measure cardiovascular and orthostatic challenge. Additionally, changes in various blood parameters were measured as well as the effects of exercise countermeasure on these measurements. Results: There were no differences at baseline in main characteristics between the control and exercise groups. The exercise group maintained V̇O2peak levels similar to baseline whereas it decreased in the control group following 14 days of HDBR. Body weight significantly decreased in both groups. Total and leg lean masses decreased in both groups. However, total body fat mass decreased only in the exercise group. Isometric and isokinetic knee extension muscle strength was significantly reduced in both groups. Peak velocity, flight height and flight time were significantly reduced in both groups with HDBR. Conclusion: In this first Canadian HDBR study in older adults, an exercise countermeasure helped maintain aerobic fitness and lean body mass without affecting the reduction of knee extension strength. However, it was ineffective in protecting against orthostatic intolerance. These results support HIIT as a promising approach to preserve astronaut health and functioning during space missions, and to prevent deconditioning as a result of hospitalization in older adults.
DOI: 10.25582/data.2019-12.1907689/2076082
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2020-01.1914999/2076083
title: Data for EMSL Project 51127 from January 2020
DOI: 10.25582/data.2019-12.1902954/2076084
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1906855/2076085
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1906399/2076086
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1900884/2076087
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2020-01.1915345/2076088
title: Data for EMSL Project 51127 from January 2020
DOI: 10.25582/data.2019-12.1899486/2076089
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1906233/2076090
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1907863/2076091
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1898806/2076092
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1907153/2076093
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1907879/2076094
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1908885/2076095
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2020-01.1911540/2076096
title: Data for EMSL Project 51127 from January 2020
DOI: 10.23728/b2share.b31c485e412f459d86d3a4422d206f03
title: EUDAT CDI Brochure

description: This is the brochure of the EUDAT Collaborative Data Infrastructure. The EUDAT Collaborative Data Infrastructure (or EUDAT CDI) is one of the largest infrastructures collectively providing integrated data services and resources supporting research in Europe. It is sustained by a network of more than 20 European research organisations, data and computing centres. This infrastructure and its services are continuously being developed in close collaboration with over 50 research communities spanning across many different research disciplines. EUDAT services and the data they handle are guaranteed by 10-year collaboration agreements that maintain the collaborative data infrastructure.
DOI: 10.25582/data.2020-01.1911295/2076097
title: Data for EMSL Project 51127 from January 2020
DOI: 10.25582/data.2020-01.1911422/2076098
title: Data for EMSL Project 51127 from January 2020
DOI: 10.6084/m9.figshare.24131187
title: Supplementary Material for: Functional characterization of gonadotropin-releasing hormone and corazonin signaling systems in Pacific abalone: toward reclassification of invertebrate neuropeptides

description: Introduction: The proposed evolutionary origins and corresponding nomenclature of bilaterian gonadotropin-releasing hormone (GnRH)-related neuropeptides have changed tremendously with the aid of receptor deorphanization. However, the reclassification of the GnRH and corazonin (CRZ) signaling systems in Lophotrochozoa remains unclear. Methods: We characterized GnRH and CRZ receptors in the mollusk Pacific abalone, Haliotis discus hannai (Hdh), by phylogenetic and gene expression analyses, bioluminescence-based reporter, western blotting, substitution of peptide amino acids, in vivo neuropeptide injection, and RNA interference assays. Results: Two Hdh CRZ-like receptors (Hdh-CRZR-A and Hdh-CRZR-B) and three Hdh GnRH-like receptors (Hdh-GnRHR1-A, Hdh-GnRHR1-B, and Hdh-GnRHR2) were identified. In phylogenetic analysis, Hdh-CRZR-A and -B grouped within the CRZ-type receptors, whereas Hdh-GnRHR1-A/-B and Hdh-GnRHR2 clustered within the GnRH/adipokinetic hormone (AKH)/CRZ-related peptide-type receptors. Hdh-CRZR-A/-B and Hdh-GnRHR1-A were activated by Hdh-CRZ (pQNYHFSNGWHA-NH2) and Hdh-GnRH (pQISFSPNWGT-NH2), respectively. Hdh-CRZR-A/-B dually coupled with the Gαq and Gαs signaling pathways, whereas Hdh-GnRHR1-A was linked only with Gαq signaling. Analysis of substituted peptides, [I2S3]Hdh-CRZ and [N2Y3H4]Hdh-GnRH, and in silico docking models revealed that the N-terminal amino acids of the peptides are critical for the selectivity of Hdh-CRZR and Hdh-GnRHR. Two precursor transcripts for Hdh-CRZ and Hdh-GnRH peptides and their receptors were mainly expressed in the neural ganglia, and their levels increased in starved abalones. Injection of Hdh-CRZ peptide into abalones decreased food consumption, whereas Hdh-CRZR knockdown increased food consumption. Moreover, Hdh-CRZ induced germinal vesicle breakdown in mature oocytes. Conclusion: Characterization of Hdh-CRZRs and Hdh-GnRHRs and their cognate peptides provides new insight into the evolutionary route of GnRH-related signaling systems in bilaterians.
DOI: 10.25582/data.2019-12.1898183/2076099
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1900530/2076100
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1906115/2076101
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1906777/2076102
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1907785/2076103
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2020-01.1910431/2076104
title: Data for EMSL Project 51127 from January 2020
DOI: 10.25582/data.2019-11.1894937/2076105
title: Data for EMSL Project 51127 from November 2019
DOI: 10.25582/data.2019-11.1895023/2076106
title: Data for EMSL Project 51127 from November 2019
DOI: 10.25582/data.2019-12.1903301/2076107
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1907214/2076108
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1899496/2076109
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2020-01.1911685/2076110
title: Data for EMSL Project 51127 from January 2020
DOI: 10.25582/data.2019-11.1894828/2076111
title: Data for EMSL Project 51127 from November 2019
DOI: 10.25582/data.2019-12.1903547/2076112
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2020-01.1910189/2076113
title: Data for EMSL Project 51127 from January 2020
DOI: 10.25582/data.2020-01.1911288/2076114
title: Data for EMSL Project 51127 from January 2020
DOI: 10.25582/data.2020-01.1911435/2076115
title: Data for EMSL Project 51127 from January 2020
DOI: 10.25582/data.2019-12.1900882/2076116
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1903111/2076117
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1903233/2076118
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2020-01.1911518/2076119
title: Data for EMSL Project 51127 from January 2020
DOI: 10.6084/m9.figshare.24288052.v1
title: Supplementary Material for: Successful Combination of Olaparib and 225Ac-Dotatate in a Patient with NET G3 and BRCA mutation

description: Based on the results of the NETTER-1 trial, peptide receptor radionuclide therapy (PRRT) with Lutetium-177 (177Lu) –DOTATATE is authorized for the treatment of neuroendocrine tumors (NET) grade 1 (G1) and G2 of the intestine. After the failure of 177Lu‑DOTATATE, targeted alpha‑particle therapy (TAT) may be a possible treatment option. Here, we present a patient with cancer of unknown primary (CUP) NET G2 later G3. The patient was referred to our hospital with urosepsis due to a second-degree urinary retention. After stent insertion, a contrast-enhanced computed tomography (CT) revealed a huge pelvic tumor without metastasis. Initially the patient had undergone surgical treatment. Later the patient developed liver metastasis and was treated by 177Lu‑DOTATATE therapy and four lines of systemic therapy. A disease progression was observed and with the knowledge of a germline BRCA1 mutation, the patient was treated with TAT (Actinium-225 (225Ac)-DOTATATE) combined with olaparib. The patient achieved a significant treatment response for 12 month indicating that a combination therapy with an alpha emitter plus olaparib might deserve further investigations in clinical trials.
DOI: 10.25582/data.2019-12.1902096/2076120
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1903548/2076121
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1906803/2076122
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1907055/2076123
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-11.1894804/2076124
title: Data for EMSL Project 51127 from November 2019
DOI: 10.25582/data.2019-12.1906874/2076125
title: Data for EMSL Project 51127 from December 2019
DOI: 10.6084/m9.figshare.24190506
title: Supplementary Material for: Endovascular Treatment Plus Medical Treatment vs Medical Treatment Alone in Ischemic Stroke: A Systematic Review and Meta-analysis

description: Introduction This study was conducted to assess the hypothesis that endovascular treatment in addition to medical treatment improve stroke mortality and post-stroke disability. Methods In this systematic review and meta-analysis, the studies were included if they were randomized controlled trials in design and compared between endovascular treatment and medical therapy vs medical therapy alone in stroke management. Results The search yielded 22 articles that included 5,049 patients. The analysis showed significant association between the intervention and reduction in disability measured by Modified Rankin Scale (mRS) (mRS=0-2) (OR=1.61; 95%CI:1.27-2.06) and National Institute of Health Stroke Scale (NIHSS) (NIHSS=0-15) (OR=2.13; 95%CI: 1.04-4.34). Also, we found a significant difference in disability scores between the intervention and the medical therapy group (mRS WMD=-0.59; 95%CI: -1.15- -0.02, NIHSS WMD= -4.52; 95%CI: -6.32- -2.72). Additionally, there was significant reduction in mortality in the intervention group (OR=0.79; 95%CI: 0.68-0.92). There was no significant difference in the rate of any serious adverse effects between the two study groups except for asymptomatic intracerebral hemorrhage. Conclusion Our study provides strong evidence stemmed from randomized clinical trials that endovascular treatment combined with medical therapy is superior to medical therapy alone in the management of stroke.
DOI: 10.6084/m9.figshare.24190506.v1
title: Supplementary Material for: Endovascular Treatment Plus Medical Treatment vs Medical Treatment Alone in Ischemic Stroke: A Systematic Review and Meta-analysis

description: Introduction This study was conducted to assess the hypothesis that endovascular treatment in addition to medical treatment improve stroke mortality and post-stroke disability. Methods In this systematic review and meta-analysis, the studies were included if they were randomized controlled trials in design and compared between endovascular treatment and medical therapy vs medical therapy alone in stroke management. Results The search yielded 22 articles that included 5,049 patients. The analysis showed significant association between the intervention and reduction in disability measured by Modified Rankin Scale (mRS) (mRS=0-2) (OR=1.61; 95%CI:1.27-2.06) and National Institute of Health Stroke Scale (NIHSS) (NIHSS=0-15) (OR=2.13; 95%CI: 1.04-4.34). Also, we found a significant difference in disability scores between the intervention and the medical therapy group (mRS WMD=-0.59; 95%CI: -1.15- -0.02, NIHSS WMD= -4.52; 95%CI: -6.32- -2.72). Additionally, there was significant reduction in mortality in the intervention group (OR=0.79; 95%CI: 0.68-0.92). There was no significant difference in the rate of any serious adverse effects between the two study groups except for asymptomatic intracerebral hemorrhage. Conclusion Our study provides strong evidence stemmed from randomized clinical trials that endovascular treatment combined with medical therapy is superior to medical therapy alone in the management of stroke.
DOI: 10.25582/data.2019-12.1907025/2076126
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1909615/2076127
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1906337/2076128
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2020-01.1911319/2076129
title: Data for EMSL Project 51127 from January 2020
DOI: 10.25582/data.2020-01.1915060/2076130
title: Data for EMSL Project 51127 from January 2020
DOI: 10.25582/data.2020-01.1910087/2076131
title: Data for EMSL Project 51127 from January 2020
DOI: 10.25582/data.2019-11.1894883/2076132
title: Data for EMSL Project 51127 from November 2019
DOI: 10.25582/data.2020-01.1909739/2076133
title: Data for EMSL Project 51127 from January 2020
DOI: 10.25582/data.2019-11.1894930/2076134
title: Data for EMSL Project 51127 from November 2019
DOI: 10.25582/data.2019-11.1894728/2076135
title: Data for EMSL Project 51127 from November 2019
DOI: 10.25582/data.2019-12.1907872/2076136
title: Data for EMSL Project 51127 from December 2019
DOI: 10.6084/m9.figshare.24279460.v1
title: Supplementary Material for: A German-wide systematic study on mobilization and collection of hematopoietic stem cells in poor mobilizer patients with multiple myeloma prior to autologous stem cell transplantation

description: Introduction: In patients with a clinical indication for autologous hematopoietic stem cell transplantation (ASCT) sufficient mobilization of CD34+ precursor cells into peripheral blood is essential to ensure adequate hematopoietic stem cell (HSC) collection prior to intensive therapy. However, with standard granulocyte-colony stimulating factor (G-CSF)-based mobilization schemes, an important minority of patients fail to mobilize sufficient (e.g., &gt; 10/µL) CD34+ cell counts into the peripheral blood and are considered as poor mobilizers (PM). Because failure to achieve sufficient CD34+ cell mobilization can negatively affect important clinical treatment endpoints, the use of plerixafor (PLX) was approved to increase CD34+ mobilization in PM patients. Methods: The German non-interventional, multicenter, open-label, prospective OPTIMOB study evaluated HSC mobilization strategies prior to planned ASCT in adult patients with hematologic malignancies (lymphomas or MM) focusing on PM patients. PM patients were defined as follows: (1) never achieving ≥ 20 CD34+ cells/µL before 1st apheresis, (2) receiving PLX at any time point of mobilization, (3) their initially planned stem cell yield had to be reduced, or (4) they had not received apheresis due to low CD34+ count in peripheral blood. Results: 168 of 475 MM patients (35%) participating in the OPTIMOB study were classified as PM,155 of them (92%) received PLX (PM+PLX) during the study. PM patients were 40 to 78 years old, slightly more often male (n=97, 58%), mostly newly diagnosed (n=146, 87%) and received highly individualized previous treatments. 94 of the PMs underwent chemotherapy mobilization (65%), 51 patients (35%) received steady state mobilization with G-CSF only during 1st mobilization attempt. 92% of the total PM population (n=155) underwent apheresis, 78% of them (n=117) achieved &gt; 2.0 x 10^6 CD34+ cells/kg body weight on the 1st day of apheresis. PM+PLX had a higher median total collection result than those PM patients without PLX support (7.2 vs 5.7 x 10^6 CD34+ cells/kg body weight). In total, ASCT was performed in 136 PM+PLX (88%) vs. 8 PM-PLX patients (62%). Discussion/Conclusion: The OPTIMOB study showed that a considerable proportion of adult MM patients in Germany are PMs. Even though most of PMs were supported with PLX in the OPTIMOB study, PM-PLX also successfully mobilized HSCs, allowing ASCT in majority of all PMs. However, further analyses are required for treatment optimization in PMs.
DOI: 10.25582/data.2019-11.1894897/2076137
title: Data for EMSL Project 51127 from November 2019
DOI: 10.25582/data.2019-12.1907051/2076138
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1907079/2076139
title: Data for EMSL Project 51127 from December 2019
DOI: 10.6084/m9.figshare.24316567
title: Cluster conformations from MD simulations of wt<i>Pf</i>DHFR, qm<i>Pf</i>DHFR, and <i>h</i>DHFR complexed with PYR, P218, MTX, PRA, PME.

description: Cluster conformations from MD simulations of wt<i>Pf</i>DHFR, qm<i>Pf</i>DHFR, and <i>h</i>DHFR complexed with PYR, P218, MTX, PRA, PME. It can be used to investigate binding interactions of the wt-qmpfDHFR and human DHFR.
DOI: 10.6084/m9.figshare.24316567.v1
title: Cluster conformations from MD simulations of wt<i>Pf</i>DHFR, qm<i>Pf</i>DHFR, and <i>h</i>DHFR complexed with PYR, P218, MTX, PRA, PME.

description: Cluster conformations from MD simulations of wt<i>Pf</i>DHFR, qm<i>Pf</i>DHFR, and <i>h</i>DHFR complexed with PYR, P218, MTX, PRA, PME. It can be used to investigate binding interactions of the wt-qmpfDHFR and human DHFR.
DOI: 10.25582/data.2019-11.1894796/2076140
title: Data for EMSL Project 51127 from November 2019
DOI: 10.25582/data.2019-12.1907199/2076141
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2020-01.1911455/2076142
title: Data for EMSL Project 51127 from January 2020
DOI: 10.6084/m9.figshare.24316324
title: 2023_10_JMSE_1

description: This data set includes all relevant data in the manuscript of JMSE_Optimal combination bootstrap particle filters.
DOI: 10.6084/m9.figshare.24316324.v1
title: 2023_10_JMSE_1

description: This data set includes all relevant data in the manuscript of JMSE_Optimal combination bootstrap particle filters.
DOI: 10.25582/data.2020-01.1909963/2076143
title: Data for EMSL Project 51127 from January 2020
DOI: 10.25582/data.2020-01.1911334/2076144
title: Data for EMSL Project 51127 from January 2020
DOI: 10.25582/data.2019-12.1902935/2076145
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1906148/2076146
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-11.1894881/2076147
title: Data for EMSL Project 51127 from November 2019
DOI: 10.25582/data.2019-12.1906453/2076148
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2020-01.1915307/2076149
title: Data for EMSL Project 51127 from January 2020
DOI: 10.25582/data.2019-12.1895565/2076150
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1907755/2076151
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1907900/2076152
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1908516/2076153
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1902919/2076154
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2020-01.1911303/2076155
title: Data for EMSL Project 51127 from January 2020
DOI: 10.25582/data.2019-12.1907809/2076156
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1906372/2076157
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1907687/2076158
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1907841/2076159
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2020-01.1911343/2076160
title: Data for EMSL Project 51127 from January 2020
DOI: 10.25582/data.2019-12.1907741/2076161
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-11.1894727/2076162
title: Data for EMSL Project 51127 from November 2019
DOI: 10.25582/data.2020-01.1910923/2076163
title: Data for EMSL Project 51127 from January 2020
DOI: 10.25582/data.2019-12.1900450/2076164
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2020-01.1910389/2076165
title: Data for EMSL Project 51127 from January 2020
DOI: 10.25582/data.2019-12.1907994/2076166
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1900466/2076167
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1906491/2076168
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1906508/2076169
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1906375/2076170
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-11.1894829/2076171
title: Data for EMSL Project 51127 from November 2019
DOI: 10.25582/data.2019-12.1902097/2076172
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-12.1908057/2076173
title: Data for EMSL Project 51127 from December 2019
DOI: 10.25582/data.2019-11.1894929/2076174
title: Data for EMSL Project 51127 from November 2019
DOI: 10.25582/data.2020-01.1911408/2076175
title: Data for EMSL Project 51127 from January 2020
DOI: 10.25582/data.2020-10.2073856/2076214
title: Data for EMSL Project 51129 from October 2020
DOI: 10.25582/data.2020-10.2072446/2076215
title: Data for EMSL Project 51129 from October 2020
DOI: 10.25582/data.2020-10.2073851/2076216
title: Data for EMSL Project 51129 from October 2020
DOI: 10.25582/data.2020-10.2074887/2076217
title: Data for EMSL Project 51129 from October 2020